Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation

Table 1 Baseline patient demographics and clinical characteristics in the tacrolimus and cyclosporine A groups n (%)

	Total (n = 689)	TAC (n = 529)	CSA (n = 160)	P value
Age (yr)	44.94 ± 9.68	44.70 ± 9.25	45.73 ± 10.98	NS
Gender (male/female)	575/114	448/81	127/33	NS
Donor type (DDLT/LDLT)	511/178	368/161	143/17	< 0.001
MELD score	13.77 ± 7.77	13.54 ± 7.96	14.54 ± 7.07	NS
Pre-LT renal dysfunction	61 (8.9)	46 (8.7)	15 (9.4)	NS
Post-LT AKI	108 (15.7)	80 (15.1)	28 (17.5)	NS
Post-LT AR	78 (11.3)	53 (10.0)	25 (15.6)	NS
Post-LT CR	18 (2.6)	13 (2.5)	5 (3.1)	NS
Primary diagnosis				NS
Tumors	344 (49.9)	265 (50.1)	79 (49.4)
Cirrhosis	232 (33.7)	182 (34.4)	50 (31.3)
Chronic active hepatitis	54 (7.8)	36 (6.8)	18 (11.3)
Others	59 (8.6)	46 (8.7)	13 (8.1)
Viral infection				NS
HBV infection	564 (81.9)	435 (82.2)	129 (80.6)
HCV infection	9 (1.3)	8 (1.5)	1 (0.6)

Age: Age at transplantation; LT: Liver transplantation; DDLT: Deceased donor liver transplantation; LDLT: Living donor liver transplantation; MELD: Mayo end-stage liver disease; AKI: Acute kidney injury; AR: Acute rejection; CR: Chronic rejection; HBV: Hepatitis B virus; HCV: Hepatitis C virus; NS: No significance; TAC: Tacrolimus; CSA: Cyclosporine A.